Synthesis of Protein Kinase Inhibitors

  • F. Scarpita Sicor S.r.l., Rho, Italy,
  • A. Canavesi Sicor S.r.l., Rho, Italy,
  • A. Jegorov Teva Czech Industries s.r.o., Opava, Czech Republic

Abstrakt

Two procedures have been developed for the synthesis of sorafenib tosylate. The aim of the development was to minimize production of symmetric ureas in the course of synthesis, which create the major impurities of the preceeding processes and are difficult to remove. The major achievements were the purity of sorafenib thus obtained (< 99.8 %, HPLC) and possibility to scale up the syntheses.
Publikované
2011-05-15
Sekce
Články